CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway
Hepatology International · 2024
DOI: 10.1007/s12072-024-10696-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology International, 2024. Verfasst von Su-Su Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Oncology, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Sorafenib, Snail Family Transcription Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Xiamen Municipal Bureau of Science and Technology.
Abstract (Originalsprache)
Background
Chromobox Homolog 1 (CBX1) plays a crucial role in the pathogenesis of numerous diseases, including the evolution and advancement of diverse cancers. The role of CBX1 in pan-cancer and its mechanism in hepatocellular carcinoma (HCC), however, remains to be further investigated.
Methods
Bioinformatics approaches were harnessed to scrutinize CBX1’s expression profile, its association with tumor staging, and its potential impact on patient outcomes across various cancers. Single-cell RNA sequencing data facilitated the investigation of CBX1 expression patterns at the individual cell level. The CBX1 expression levels in HCC and adjacent non-tumor tissues were quantified through Real-Time Polymerase Chain Reaction (RT-PCR), Western Blotting (WB), and Immunohistochemical analyses. A tissue microarray was employed to explore the relationship between CBX1 levels, patient prognosis, and clinicopathological characteristics in HCC. Various in vitro assays—including CCK-8, colony formation, Transwell invasion, and scratch tests—were conducted to assess the proliferative and motility properties of HCC cells upon modulation of CBX1 expression. Moreover, the functional impact of CBX1 on HCC was further discerned through xenograft studies in nude mice.
Results
CBX1 was found to be upregulated in most cancer forms, with heightened expression correlating with adverse patient prognoses. Within the context of HCC, elevated levels of CBX1 were consistently indicative of poorer clinical outcomes. Suppression of CBX1 through knockdown methodologies markedly diminished HCC cell proliferation, invasive capabilities, migratory activity, Epithelial−mesenchymal transition (EMT) processes, and resistance to Tyrosine kinase inhibitors (TKIs). Contrastingly, CBX1 augmentation facilitated the opposite effects. Subsequent investigative efforts revealed CBX1 to be a promoter of EMT and a contributor to increased TKI resistance within HCC cells, mediated via the IGF-1R/AKT/SNAIL signaling axis. The oncogenic activities of CBX1 proved to be attenuable either by AKT pathway inhibition or by targeted silencing of IGF-1R.
Conclusions
The broad overexpression of CBX1 in pan-cancer and specifically in HCC positions it as a putative oncogenic entity. It is implicated in forwarding HCC progression and exacerbating TKI resistance through its interaction with the IGF-1R/AKT/SNAIL signaling cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatic Oncology, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, China.
- Department of Hepatic Oncology, Liver Cancer Institute, Key Laboratory for Carcinogenesis and Cancer Invasion (Ministry of Education), Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
- Department of Liver Surgery, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, China.
- Department of Liver Cancer, Shanghai Geriatrics Medical Center, 2560 Chunshen Road, Shanghai, 201104, China.
- Department of Liver Surgery, Liver Cancer Institute, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Zhongshan Hospital, Fudan University, Shanghai, 200032, China. huang.cheng@zs-hospital.s…
- Department of Hepatic Oncology, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, 361015, China. zhang.boheng@zs-hospital.sh.cn.
Förderung
- Natural Science Foundation of Fujian Province
- Xiamen Municipal Bureau of Science and Technology
Zitieren
APA
Zheng, S. S., Wu, J. F., Wu, W. X., Hu, J. W., Zhang, D., Huang, C., & Zhang, B. H. (2024). CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway. Hepatology International. https://doi.org/10.1007/s12072-024-10696-0
Vancouver
Zheng SS, Wu JF, Wu WX, Hu JW, Zhang D, Huang C, et al. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway. Hepatology International. 2024. doi:10.1007/s12072-024-10696-0
BibTeX
@article{Zheng2024,
author = {Zheng, Su-Su and Wu, Jing-Fang and Wu, Wei-Xun and Hu, Jin-Wu and Zhang, Dai and Huang, Cheng and Zhang, Bo-Heng},
title = {CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway},
journal = {Hepatology International},
year = {2024},
doi = {10.1007/s12072-024-10696-0}
}
EUVIMED